Xeris Biopharma Holdings, Inc.
$6.25
0%
2026-04-21 10:21:00
www.xerispharma.com
NMS: XERS
Explore Xeris Biopharma Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.04 B
Current Price
$6.25
52W High / Low
$10.08 / $3.95
Stock P/E
1,885.02
Book Value
$0.08
Dividend Yield
—
ROCE
9.09%
ROE
-6.96%
Face Value
—
EPS
$0
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
435
Beta
0.99
Debt / Equity
1,885.44
Current Ratio
2.19
Quick Ratio
1.57
Forward P/E
15.79
Price / Sales
3.46
Enterprise Value
$1.16 B
EV / EBITDA
31.19
EV / Revenue
3.96
Rating
Strong Buy
Target Price
$11.14
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
Cons
- Return on equity is on the weaker side.
- Leverage is relatively high.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Generate Biomedicines, Inc. | $12.12 | — | $1.59 B | — | -94.79% | -81.72% | $15.32 / $11 | $-12.24 |
| 2. | BioRestorative Therapies, Inc. | $0.26 | — | $6.72 M | — | -4386.1% | -3.2% | $2.04 / $0.19 | $0.04 |
| 3. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 4. | Artiva Biotherapeutics, Inc. | $13.39 | — | $310.19 M | — | -76.21% | -56.55% | $13.2 / $1.47 | $4.53 |
| 5. | ADMA Biologics, Inc. | $10.88 | 17.68 | $2.6 B | — | 34.51% | 35.56% | $25.67 / $7.21 | $2.01 |
| 6. | Beam Therapeutics Inc. | $31.19 | — | $3.2 B | — | -27.72% | -8.11% | $36.44 / $15.35 | $12.48 |
| 7. | Larimar Therapeutics, Inc. | $4.81 | — | $499.68 M | — | -212.84% | -1.33% | $6.42 / $1.73 | $0.94 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 85.81 M | 74.38 M | 71.54 M | 60.12 M | 60.1 M | — |
| Operating Profit | 16.77 M | 6.73 M | 4.48 M | -3.09 M | 1.68 M | — |
| Net Profit | 11.08 M | 0.62 M | -1.93 M | -9.22 M | -5.11 M | — |
| EPS in Rs | 0.06 | 0 | -0.01 | -0.05 | -0.03 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 291.85 M | 203.07 M | 163.91 M | 110.25 M |
| Operating Profit | 24.9 M | -33.65 M | -44.01 M | -81.94 M |
| Net Profit | 0.55 M | -54.84 M | -62.26 M | -94.66 M |
| EPS in Rs | 0 | -0.32 | -0.36 | -0.55 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 383.53 M | 323.06 M | 322.6 M | 344.52 M |
| Total Liabilities | 369.84 M | 352.68 M | 329.38 M | 299.33 M |
| Equity | 13.69 M | -29.61 M | -6.78 M | 45.19 M |
| Current Assets | 240.31 M | 167.66 M | 156.26 M | 186.82 M |
| Current Liabilities | 109.57 M | 100.44 M | 95.19 M | 73.62 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 28.63 M | -36.98 M | -47.02 M | -102.89 M |
| Investing CF | -0.7 M | 4.88 M | -6 M | 34.46 M |
| Financing CF | 11.39 M | 36.17 M | -1.61 M | 127.47 M |
| Free CF | 27.93 M | -37.85 M | -49.29 M | -103.42 M |
| Capex | -0.7 M | -0.87 M | -2.26 M | -0.52 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 23.89% | 48.68% | — | — |
| Earnings Growth % | 11.92% | 34.23% | — | — |
| Profit Margin % | -27% | -37.98% | -85.86% | — |
| Operating Margin % | -16.57% | -26.85% | -74.32% | — |
| Gross Margin % | 81.86% | 82.52% | 79.47% | — |
| EBITDA Margin % | -6.89% | -14.48% | -62.87% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.